6-K Current report (foreign)
99.1 Additional exhibits
AKTX similar filings
20 Jul 21 Current report (foreign)
7 Jul 21 Akari Therapeutics Announces Private Placement
1 Jul 21 Current report (foreign)
29 Jun 21 Current report (foreign)
7 Jun 21 This Document Is Important and Requires Your Immediate Attention
28 Apr 21 Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid
20 Apr 21 Current report (foreign)
AKTX Dashboard
AKTX Dashboard Financials Data Institutional Insider News Filings Reddit ESG Shorts Patents 6-K Filing
AKTX Akari Therapeutics 6-KCurrent report (foreign)
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
Commission file number: 001-36288
Akari Therapeutics, Plc
(Translation of registrant's name into English)
75/76 Wimpole Street
London W1G 9RT
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
On June 29, 2021, Akari Therapeutics, Plc (the "Company") issued unaudited interim condensed consolidated financial statements as of March 31, 2021, prepared in accordance with generally accepted accounting principles in the United States, together with the Company's Management Discussion and Analysis of Financial Condition and Results of Operations for the same period. Attached hereto and incorporated by reference herein are the following exhibits:
99.1 Unaudited Interim Condensed Consolidated Financial Statements as of March 31, 2021
99.2 Management Discussion and Analysis of Financial Condition and Results of Operations as of March 31, 2021
In addition, on June 29, 2021, the Company issued a press release announcing its first quarter 2021 financial results and recent clinical progress highlights. A copy of the press release is attached hereto as Exhibit 99.3, and incorporated herein by reference.
The information contained in Exhibits 99.1 and 99.2 and the statements under "First Quarter 2021 Financial Results", the accompanying financial statements and "Cautionary Note Regarding Forward-Looking Statements" of Exhibit 99.3 are hereby incorporated by reference into all effective registration statements filed by the Company under the Securities Act of 1933.
Exhibit No.
99.3 Press release dated June 29, 2021
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
(Registrant)
By: /s/ Clive Richardson
Name: Clive Richardson
Chief Executive Officer and Chief Operating Officer